RGNX – REGENXBIO Inc.
REGENXBIO Inc.RGNX
$11.14Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $563,941,248.00
EPSttm : -3.46
REGENXBIO Inc.
$11.14
3.21%$0.37Float Short %
9.86
Margin Of Safety %
Put/Call OI Ratio
0.7
EPS Next Q Diff
-0.19
EPS Last/This Y
1.39
EPS This/Next Y
0.83
Price
11.14
Target Price
31.25
Analyst Recom
1.42
Performance Q
38.73
Relative Volume
0.95
Beta
1.16
Ticker: RGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | RGNX | 12.64 | 0.89 | 0.44 | 3578 |
| 2025-10-21 | RGNX | 13.09 | 0.89 | 0.01 | 3615 |
| 2025-10-22 | RGNX | 12.19 | 0.77 | 0.41 | 3916 |
| 2025-10-23 | RGNX | 12.55 | 0.77 | 0.35 | 3916 |
| 2025-10-24 | RGNX | 13.04 | 0.77 | 0.00 | 3930 |
| 2025-10-27 | RGNX | 13.62 | 0.76 | 0.00 | 3954 |
| 2025-10-28 | RGNX | 13.16 | 0.71 | 0.00 | 4134 |
| 2025-10-29 | RGNX | 12.83 | 0.69 | 0.00 | 4199 |
| 2025-10-30 | RGNX | 12.8 | 0.68 | 0.00 | 4241 |
| 2025-10-31 | RGNX | 12.77 | 0.68 | 0.00 | 4243 |
| 2025-11-03 | RGNX | 11.99 | 0.68 | 3.12 | 4227 |
| 2025-11-04 | RGNX | 11.55 | 0.72 | 0.00 | 4379 |
| 2025-11-05 | RGNX | 11.59 | 0.72 | 0.06 | 4393 |
| 2025-11-06 | RGNX | 11.18 | 0.71 | 0.78 | 4408 |
| 2025-11-07 | RGNX | 11.22 | 0.71 | 0.00 | 4440 |
| 2025-11-10 | RGNX | 11.03 | 0.71 | 0.11 | 4438 |
| 2025-11-11 | RGNX | 11.56 | 0.72 | 0.00 | 4432 |
| 2025-11-12 | RGNX | 11.6 | 0.71 | 0.02 | 4445 |
| 2025-11-13 | RGNX | 11.66 | 0.70 | 0.09 | 4503 |
| 2025-11-14 | RGNX | 11.51 | 0.70 | 0.02 | 4492 |
| 2025-11-17 | RGNX | 11.14 | 0.70 | 0.03 | 4490 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | RGNX | 12.64 | -11.0 | 266.4 | -2.28 |
| 2025-10-21 | RGNX | 13.06 | -11.0 | 258.1 | -2.28 |
| 2025-10-22 | RGNX | 12.19 | -11.0 | 240.7 | -2.28 |
| 2025-10-23 | RGNX | 12.56 | -11.0 | 257.6 | -2.28 |
| 2025-10-24 | RGNX | 13.02 | -11.0 | 258.3 | -2.28 |
| 2025-10-27 | RGNX | 13.64 | -11.0 | 260.3 | -2.28 |
| 2025-10-28 | RGNX | 13.16 | -11.0 | 246.8 | -2.28 |
| 2025-10-29 | RGNX | 12.84 | -11.0 | 248.1 | -2.28 |
| 2025-10-30 | RGNX | 12.82 | -11.0 | 252.0 | -2.28 |
| 2025-10-31 | RGNX | 12.77 | -11.0 | 251.6 | -2.28 |
| 2025-11-03 | RGNX | 11.99 | -11.0 | 241.9 | -2.28 |
| 2025-11-04 | RGNX | 11.52 | -11.0 | 245.4 | -2.28 |
| 2025-11-05 | RGNX | 11.61 | -11.0 | 253.1 | -2.28 |
| 2025-11-06 | RGNX | 11.19 | -11.0 | 245.7 | -2.28 |
| 2025-11-07 | RGNX | 11.21 | -11.0 | 238.8 | -2.28 |
| 2025-11-10 | RGNX | 11.02 | 117.0 | 239.3 | -2.28 |
| 2025-11-11 | RGNX | 11.55 | 117.0 | 250.1 | -3.20 |
| 2025-11-12 | RGNX | 11.60 | 117.0 | 242.9 | -3.20 |
| 2025-11-13 | RGNX | 11.64 | 117.0 | 242.8 | -3.20 |
| 2025-11-14 | RGNX | 11.52 | 26.3 | 240.7 | -3.20 |
| 2025-11-17 | RGNX | 11.14 | 26.7 | 237.1 | -3.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | RGNX | -1.29 | -0.25 | 10.80 |
| 2025-10-21 | RGNX | -1.29 | -0.25 | 10.80 |
| 2025-10-22 | RGNX | -1.29 | -0.25 | 10.80 |
| 2025-10-23 | RGNX | -1.29 | -0.25 | 10.80 |
| 2025-10-24 | RGNX | -1.29 | -0.25 | 10.80 |
| 2025-10-27 | RGNX | -1.29 | -2.76 | 10.57 |
| 2025-10-28 | RGNX | -1.29 | -2.76 | 10.57 |
| 2025-10-29 | RGNX | -1.29 | -2.76 | 10.57 |
| 2025-10-30 | RGNX | -1.29 | -2.76 | 10.57 |
| 2025-10-31 | RGNX | -1.29 | -2.76 | 10.57 |
| 2025-11-03 | RGNX | -1.29 | -2.35 | 10.57 |
| 2025-11-04 | RGNX | -1.29 | -2.35 | 10.57 |
| 2025-11-05 | RGNX | -1.29 | -2.35 | 10.57 |
| 2025-11-06 | RGNX | -1.29 | -2.35 | 10.57 |
| 2025-11-07 | RGNX | -1.29 | -2.35 | 10.57 |
| 2025-11-10 | RGNX | -1.29 | -2.26 | 10.55 |
| 2025-11-11 | RGNX | -1.29 | -2.26 | 10.55 |
| 2025-11-12 | RGNX | -1.29 | -2.26 | 9.83 |
| 2025-11-13 | RGNX | -1.29 | -2.26 | 9.83 |
| 2025-11-14 | RGNX | -1.29 | -2.26 | 9.81 |
| 2025-11-17 | RGNX | -0.84 | -1.83 | 9.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.2
Avg. EPS Est. Current Quarter
-0.74
Avg. EPS Est. Next Quarter
-1.39
Insider Transactions
-0.84
Institutional Transactions
-1.83
Beta
1.16
Average Sales Estimate Current Quarter
66
Average Sales Estimate Next Quarter
77
Fair Value
Quality Score
39
Growth Score
40
Sentiment Score
73
Actual DrawDown %
77.8
Max Drawdown 5-Year %
-89.4
Target Price
31.25
P/E
Forward P/E
PEG
P/S
3.5
P/B
3.49
P/Free Cash Flow
EPS
-3.49
Average EPS Est. Cur. Y
-3.2
EPS Next Y. (Est.)
-2.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-110.29
Relative Volume
0.95
Return on Equity vs Sector %
-137.1
Return on Equity vs Industry %
-122.2
EPS 1 7Days Diff
-0.9
EPS 1 30Days Diff
-0.92
EBIT Estimation
237.1
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading